Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch. bronconeumol. (Ed. impr.) ; 53(5): 245-250, mayo 2017. tab
Article in Spanish | IBECS | ID: ibc-162360

ABSTRACT

Introducción: La diabetes mellitus (DM), una enfermedad muy frecuente en México, es un factor de riesgo bien conocido para el desarrollo de tuberculosis (TB). Sin embargo, se desconoce en qué medida la DM predispone al desarrollo de reacciones adversas (RA) a los fármacos anti-tuberculosis y/o si predispone a un peor resultado en pacientes con pacientes con TB multirresistente (TB-MR) y TB extremadamente resistente (TB-XR). El objetivo principal de este estudio fue describir los resultados del tratamiento anti-tuberculosis, el impacto de la DM y la prevalencia de RA en una cohorte de pacientes con TB pulmonar MR/XR tratados en el centro de referencia nacional para TB, en la Ciudad de México. Resultados: Entre 2010 y 2015 se incluyeron 90 pacientes -73 con TB-MR (81,1%), 11 con TB pre-XR (12,2%) y 6 (6,7%) con TB-XR-, 49 (54,4%) de los cuales tenían DM y 3 con co-infección por el virus de la inmunodeficiencia humana (VIH) (3,3%). El diagnóstico se realizó mediante cultivo y pruebas de fármaco-sensibilidad (PFS) en el 98% de los pacientes y mediante prueba molecular en un caso. La presencia de DM se asoció con un mayor riesgo de RA graves, tales como nefrotoxicidad (odds ratio [OR] = 6,5; intervalo de confianza del 95% [IC 95%]: 1,9-21,8) e hipotiroidismo (OR = 8,8; IC 95%: 1,8-54,2), aunque no con peor resultado del tratamiento. onclusiones: Nuestros datos sugieren que la DM no tiene un impacto sobre los resultados del tratamiento anti-tuberculosis de segunda línea, pero los pacientes con DM tienen mayor riesgo de presentar RA graves secundarias al tratamiento, tales como nefrotoxicidad e hipotiroidismo


Introduction: Diabetes mellitus (DM), a very common disease in Mexico, is a well-known risk factor for tuberculosis (TB). However, it is not known by which extent DM predisposes to adverse events (AE) to anti-TB drugs and/or to worse outcomes in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). The main objective of this study was to describe the outcomes of TB treatment, the impact of DM and the prevalence of AE in a cohort of patients with MDR-/XDR pulmonary TB treated at the national TB referral centre in Mexico City. Results: Ninety patients were enrolled between 2010 and 2015: 73 with MDR-TB (81.1%), 11 with pre-XDR-TB (12.2%) and 6 (6.7%) with XDR-TB, including 49 (54.4%) with DM, and 3 with Human Immunodeficiency Virus (HIV) co-infection (3.3%). In 98% of patients, diagnosis was made by culture and drug susceptibility testing, while in a single case the diagnosis was made by a molecular test. The presence of DM was associated with an increased risk of serious drug-related AEs, such as nephrotoxicity (Odds Ratio [OR] = 6.5; 95% Confidence Interval [95% CI]: 1.9-21.8) and hypothyroidism (OR = 8.8; 95% CI: 1.8-54.2), but not for a worse outcome. Conclusions: Our data suggest that DM does not impact second-line TB treatment outcomes, but patients with DM have a higher risk of developing serious AEs to drug-resistant TB treatment, such as nephrotoxicity and hypothyroidism


Subject(s)
Humans , Diabetes Mellitus/epidemiology , Tuberculosis, Multidrug-Resistant/epidemiology , Risk Factors , Diabetes Complications , Antitubercular Agents/adverse effects , Drug-Related Side Effects and Adverse Reactions/epidemiology
2.
Arch Bronconeumol ; 53(5): 245-250, 2017 May.
Article in English, Spanish | MEDLINE | ID: mdl-28089216

ABSTRACT

INTRODUCTION: Diabetes mellitus (DM), a very common disease in Mexico, is a well-known risk factor for tuberculosis (TB). However, it is not known by which extent DM predisposes to adverse events (AE) to anti-TB drugs and/or to worse outcomes in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). The main objective of this study was to describe the outcomes of TB treatment, the impact of DM and the prevalence of AE in a cohort of patients with MDR-/XDR pulmonary TB treated at the national TB referral centre in Mexico City. RESULTS: Ninety patients were enrolled between 2010 and 2015: 73 with MDR-TB (81.1%), 11 with pre-XDR-TB (12.2%) and 6 (6.7%) with XDR-TB, including 49 (54.4%) with DM, and 3 with Human Immunodeficiency Virus (HIV) co-infection (3.3%). In 98% of patients, diagnosis was made by culture and drug susceptibility testing, while in a single case the diagnosis was made by a molecular test. The presence of DM was associated with an increased risk of serious drug-related AEs, such as nephrotoxicity (Odds Ratio [OR]=6.5; 95% Confidence Interval [95% CI]: 1.9-21.8) and hypothyroidism (OR=8.8; 95% CI: 1.8-54.2), but not for a worse outcome. CONCLUSIONS: Our data suggest that DM does not impact second-line TB treatment outcomes, but patients with DM have a higher risk of developing serious AEs to drug-resistant TB treatment, such as nephrotoxicity and hypothyroidism.


Subject(s)
Antitubercular Agents/adverse effects , Diabetes Mellitus, Type 2/complications , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy , Adult , Catheter-Related Infections/epidemiology , Catheter-Related Infections/etiology , Comorbidity , Disease Susceptibility , Extensively Drug-Resistant Tuberculosis/drug therapy , Extensively Drug-Resistant Tuberculosis/epidemiology , Female , HIV Infections/epidemiology , Hearing Loss/chemically induced , Hearing Loss/epidemiology , Humans , Hypertension/epidemiology , Hypothyroidism/chemically induced , Hypothyroidism/epidemiology , Kidney Diseases/chemically induced , Kidney Diseases/epidemiology , Male , Mexico/epidemiology , Middle Aged , Nausea/chemically induced , Nausea/epidemiology , Retrospective Studies , Treatment Outcome , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Pulmonary/epidemiology , Young Adult
3.
Lung Cancer ; 47(3): 361-71, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15713519

ABSTRACT

The proportions of naïve, memory and effector CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients were studied. CD8+ T subsets were identified by using a combination of the following antibodies: anti-CD45RA, anti-CD45RO, anti-CD27 and anti-CD28, as well as antibodies to other markers. Fas-positive cells were determined in each CD8+ T subset. Also, the intracellular cytokine patterns of CD4+ and CD8+ lymphocytes from pleural effusion were analysed. In naïve, memory and effector CD8+ T subsets no significant differences were observed in peripheral blood between healthy donors and cancer patients. In contrast, a high proportion of cells with memory phenotype (CD45RA-CD45RO+CD27+CD28+) and a low proportion of cells with effector phenotype (CD45RA+CD45RO-CD27-CD28-) were found in pleural effusion with respect to peripheral blood (P<0.001). The altered proportions of CD8+ T subsets in pleural effusion were not mediated by type 2 cytokines produced by CD4+ or CD8+ lymphocytes. In the effector CD8+ T subset, from peripheral blood as well as from pleural effusion, a low percentage of perforin-expressing cells was observed compared to granzyme A-expressing cells. Additionally, a high percentage of naïve CD8+ T cells expressing Fas was found. Our data suggest that: (i) terminal-differentiation process of CD8+ T cells is blocked, and (ii) early Fas-expression in CD8+ T cells, which was reflected even in peripheral blood, may lead to apoptosis of naïve cells when they reach the effector stage. All these processes may contribute to the inadequate antitumour immune response found in lung carcinoma patients.


Subject(s)
Adenocarcinoma/immunology , CD8-Positive T-Lymphocytes , Carcinoma, Non-Small-Cell Lung/immunology , Lung Neoplasms/immunology , Pleural Effusion/immunology , Aged , Antibodies/immunology , Cell Differentiation , Female , Humans , Immunologic Memory , Male , Middle Aged , Phenotype , fas Receptor/immunology
4.
Rev. Inst. Nac. Enfermedades Respir ; 10(3): 168-74, jul.-sept. 1997. tab, ilus
Article in Spanish | LILACS | ID: lil-214355

ABSTRACT

Se presentan los resultados obtenidos de un estudio retrospectivo efectuado en 1524 pacientes atendidos con diagnóstico de absceso hepático amibiano y sus complicaciones torácicas en hospitales del Estado de México, Tlaxcala e Hidalgo y en los hospitales Gea González, General de México e Instituto Nacional de Enfermedades Respiratorias del Distrito Federal durante 1991 a 1995. Se encontró que en este periodo de incidencia descendió alrededor del 50 por ciento, con una disminución acentuada en 1993. Fue más frecuente en los adultos del sexo masculino en una proporción de 3:1, el hábito alcohólico de 63.51 por ciento, predominando la ingestión de pulque. Se encontró que el 9.05 por ciento se complicó a la pleura y pulmón del hemitórax derecho. No hubo apertura a pericardio. Las radiografías simples de tórax y abdomen fueron los estudios imagenológicos más frecuentes, pero además se hicieron 102 ultrasonidos, 33 gammagrafías hepatoesplénicas y sólo en 3 se efectuó tomografía computada. En cuanto al tratamiento, todos recibieron metronidazol, se agregó emetina en 327 y cloroquina a 250. En relación a procedimientos quirúrgicos se realizó drenaje pleural en 76, decorticación en 5 y resección pulmonar en 2. Los resultados fueron satisfactorios en el 96.19 por ciento de los casos, con una mortalidad de 3.80 por ciento


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Liver Abscess, Amebic/etiology , Liver Abscess, Amebic/parasitology , Liver Abscess, Amebic/epidemiology , Drainage , Empyema, Pleural/etiology , Entamoeba histolytica/pathogenicity , Mexico , Pleural Diseases/etiology , Pleural Diseases/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...